患者様やご家族など一般の方向け臨床・治癒情報サイト　臨床研究情報ポータルサイト

ENGLISH
国立保健医療科学院
クリップした情報
×

情報をクリップできます

治験情報をこちらのホームページで一時的にクリップすることが出来ます。

削除
治験例

海外の治験の状況「1」での検索結果

絞り込み

379件の検索結果
  • 進捗状況
  • 試験名
  • 対象疾患名
  • 地域
  • 登録日
  •  

  • Authorised

  • A Phase 1/2 Study of the Safety and Efficacy of CO-1686 in Patients with Previously Treated EGFR Non-Small Cell Lung Cancer
  • Previously treated NSCLC patients who have documented evidence of an activating mutation in the EGFR gene and have failed treatment with an EGFR inhibitor such as erlotinib or gefitinib MedDRA version: 19.0 Level: LLT Classification code 10029514 Term: Non-small cell lung cancer NOS System Organ Class: 100000004864 MedDRA version: 19.0 Level: LLT Classification code 10025048 Term: Lung cancer non-small cell recurrent System Organ Class: 100000004864 ;Therapeutic area: Diseases [C] - Cancer [C04]
  • Australia, Poland, United States
  • 2013-03-04

  • Authorised

  • Study of REGN1979 (anti-CD20 and anti- CD3) and REGN2810 (anti-PD-1) in Patients with a Specific Type of Blood Cancer
  • B-cell malignancies MedDRA version: 18.1 Level: PT Classification code 10003903 Term: B-cell lymphoma refractory System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 18.1 Level: PT Classification code 10003917 Term: B-cell type acute leukaemia System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 18.1 Level: PT Classification code 10026945 Term: Mature B-cell type acute leukaemia System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 18.1 Level: PT Classification code 10067184 Term: Burkitt's leukaemia System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 18.1 Level: PT Classification code 10020267 Term: Hodgkin's disease refractory System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 18.1 Level: PT Classification code 10003890 Term: B precursor type acute leukaemia System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 18.1 Level: PT Classification code 10020266 Term: Hodgkin's disease recurrent System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 18.1 Level: PT Classification code 10003902 Term: B-cell lymphoma recurrent System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
  • Germany, Spain, United States
  • 2015-10-15

  • Authorised

  • Phase 1/2a to assess PEN-221 in somatostatin receptor 2 expressing advanced cancers
  • Somatostatin receptor 2 (SSTR2) expressing advanced cancers, including gastroenteropancreatic (GEP) cancer or lung cancer or thymus cancer or other NETs (Neuroendocrine tumour) or small cell lung cancer (SCLC) or large cell neuroendocrine carcinoma (LCNEC) of the lung.;Therapeutic area: Diseases [C] - Cancer [C04]
  • United Kingdom, United States
  • 2017-01-04

  • Authorised

  • A clinical study testing the efficacy and safety of V565 in patients with Crohn's Disease
  • Active Crohn's Disease MedDRA version: 20.0 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
  • Austria, Belgium, Canada, Czech Republic, Germany, Hungary, Netherlands, Poland, Slovakia, Ukraine, United Kingdom, United States
  • 2016-11-02

  • Authorised

  • A phase 1/2, open-label, multicenter study, designed to evaluate the safety, tolerability, the blood concentration values and efficacy of a substance called TAS0728.
  • Urothelial cancer with HER2 or HER3 mutation Biliary tract cancer with HER2 or HER3 mutation Breast cancer with HER2 or HER3 mutation Breast cancer with HER2 amplification/overexpression as per ASCO-CAP 2013 guidelines Non-small cell lung cancer (NSCLC) with HER2 or HER3 mutation Colorectal cancer (CRC) with HER2 mutation or amplification Other tumors with HER2 or HER3 mutation, amplification, or overexpression (eg, gastric or gastroesophageal junction (GEJ), endometrial) MedDRA version: 20.0 Level: PT Classification code 10061451 Term: Colorectal cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 20.0 Level: PT Classification code 10057654 Term: Breast cancer female System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 20.0 Level: PT Classification code 10004593 Term: Bile duct cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 20.0 Level: LLT Classification code 10077840 Term: Urothelial cancer of renal pelvis System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 20.0 Level: LLT Classification code 10079440 Term: Non-squamous non-small cell lung cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
  • Australia, France, Spain, United Kingdom, United States
  • 2018-01-17